Dr. Mitchell Boxer MD

Assistant Clinical Professor, Albert Einstein College of Medicine

GLG News by Dr. Mitchell Boxer MD, Assistant Clinical Professor

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Another nasal corticosteroid

August 30, 2007

Analysis of:Collegium Pharmaceutical provides update on development of its nasal inhaled steroid for allergic rhinitis | www.pipelinereview.com

A new nasal corticosteroid being released by another pharmaceutical company

Xyzal approval

August 30, 2007

Analysis of:New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com

Zyrtec will soon be available over the counter and this new product will attempt to keep the antihistamine market share for Sanofi-Aventis - although Zyrtec is presently manufactured by Pfizer. The antihistamine market is quite large and the OTC versus prescription situation is making this problematic for both physicians, patients and insurance companies.

intranasal antibiotics for chronic sinusitis

April 23, 2007

Analysis of:FDA Approves Fast Track Designation for Naryx Pharma’s Product for Chronic Sinusitis | www.naryxpharma.com

I have not found nebulized antibiotic therapy to be of great success in patients with chronic sinusitis. There are already a few pharmacies that have formulated an array of nebulized antibiotics and I have tried them in a few patients with no success.

Xolair apprehension

February 27, 2007

Analysis of:FDA Orders Black Box Anaphylaxis Warning for Omalizumab (Xolair) | www.medpagetoday.com

There is a concern about anaphylaxis secondary to Xolair administration and this may result in longer waiting times after the administration of the drug.

Evaluation of Change therapy

February 13, 2007

Analysis of:Patient Treatment Completed in Phase 3 Trial of C1-Esterase Inhibitor in Hereditary Angioedema | www.ptcommunity.com

HAE is a rare but potentially life threatening immunologic disease. If c1 esterase inhibitor is found to be effective in preventing exacerbations of HAE than this novel treatment will have a great impact on the lives of those affected and will undoubtedly replace the present treatments such as androgens in preventing attacks. It would be of interest in seeing how the European community is presently using this replacement therapy.

Page : 11 to 5 of 5

Subscribe to Updates

By RSS